{"id":1244,"date":"2024-02-29T07:40:03","date_gmt":"2024-02-29T07:40:03","guid":{"rendered":"https:\/\/www.eye-connect.org\/namd\/?page_id=1244"},"modified":"2026-06-05T15:37:13","modified_gmt":"2026-06-05T19:37:13","slug":"ce-activities","status":"publish","type":"page","link":"https:\/\/www.eye-connect.org\/namd\/ce-activities\/","title":{"rendered":"CE Activities"},"content":{"rendered":"
<\/div>

CME Activities<\/h1>\n<\/div><\/div><\/div><\/div><\/div>
<\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div>
Featured Activities<\/div>\n<\/div><\/div>
<\/div>
\"Second-Generation<\/a><\/div>
<\/div>
\n

Second-Generation Anti-VEGF Therapies for nAMD: From Clinical Trials to Practice<\/u><\/a><\/p>\n

Webinar
\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"Switching<\/a><\/div>
<\/div>
\n

Switching IVT Anti-VEGF Agents for nAMD: So Many Options, How to Choose?<\/u><\/a><\/p>\n

Webinar
\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"\"<\/a><\/div>
<\/div>
\n

When and How to Prioritize Injection Burden for nAMD<\/u><\/a><\/p>\n

Webinar
\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"Managing<\/a><\/div>
<\/div>
\n

The Human Side of nAMD: Balancing Vision, Life, and Treatment<\/u><\/a><\/p>\n

Webinar
\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div>
<\/div>
\"Getting<\/a><\/div>
<\/div>
\n

Did You Know? Getting Into the Details About Managing nAMD<\/u><\/a><\/p>\n

Patient Simulation
\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"Safety<\/a><\/div>
<\/div>
\n

Safety of the New Anti-VEGF Therapies<\/u><\/a><\/p>\n

Webinar
\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"Switching<\/a><\/div>
<\/div>
\n

Switching to a New Anti-VEGF Agent for nAMD<\/u><\/a><\/p>\n

Patient Simulation
\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"Initiating<\/a><\/div>
<\/div>
\n

Initiating New Anti-VEGF Therapies in Patients With nAMD<\/u><\/a><\/p>\n

Patient Simulation
\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div>
<\/div>
\"Translating<\/a><\/div>
<\/div>
\n

Translating the Latest Data for New Intravitreal Anti-VEGF Therapies<\/u><\/a><\/p>\n

Webinar
\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"Personalizing<\/a><\/div>
<\/div>
\n

Personalizing Treatment for nAMD Using New Anti-VEGF Therapies<\/u><\/a><\/p>\n

Webinar
\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
<\/div><\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/section>
Archived<\/div>\n<\/div><\/div>
<\/div>
\"Extending<\/a><\/div>
<\/div>
\n

Extending Treatment Durability With Next-Generation nAMD Therapies<\/a> <\/u><\/p>\n

Webinar
\nCredit Hours: 0.50 (30 min)
\nThis activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"Advances<\/a><\/div>
<\/div>
\n

Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies<\/a><\/u><\/p>\n

Infographic
\nCredit Hours: 0.50 (30 min)
\nThis activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"Improving<\/a><\/div>
<\/div>
\n

Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD<\/u><\/a><\/p>\n

Case Consult
\nCredit Hours: 0.25 (15 min)
\nThis activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"When<\/a><\/div>
<\/div>
\n

When to Start, When to Switch, and Dosing Strategy With Anti-VEGF Therapy<\/u><\/a><\/p>\n

Case Consult
\nCredit Hours: 0.25 (15 min)
\nThis activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div>
\"Success<\/a><\/div>
<\/div>
\n

Success With Extended Dosing Intervals of Anti-VEGF Therapies for nAMD<\/u><\/a><\/p>\n

Case Consult
\nCredit Hours: 0.25 (15 min)
\nThis activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
\"Strategies<\/a><\/div>
<\/div>
\n

Strategies to Reduce Vision Loss in nAMD Using Long-Acting Anti-VEGF Therapies<\/u><\/a><\/p>\n

Patient Simulation
\nCredit Hours: 0.50 (30 min)
\nThis activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div>

<\/div>
VIEW DETAILS<\/span><\/a><\/div><\/div><\/div>
<\/div><\/div>
<\/div><\/div><\/div>
<\/div>
<\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"CME Activities Featured Activities Second-Generation Anti-VEGF Therapies for nAMD: From Clinical Trials to Practice Webinar Credit Hours: 0.50 (30 min) VIEW DETAILS Switching IVT Anti-VEGF Agents for nAMD: So Many Options, How to Choose? Webinar Credit Hours: 0.50 (30 min) VIEW DETAILS When and How to Prioritize Injection Burden for nAMD Webinar Credit Hours: 0.50...","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-1244","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t